New article using Attana's technology from National University of Singapore: Immunity differences in vaccinated individuals according to age, gender, lifestyle and other diseases
The article presented quantification of serological immunity against SARS-CoV-2 variants. Differences in immunity are seen against the different variants and depending on age, sex, ethnicity and lifestyle, but e.g. high blood pressure or BMI did not show significant differences in the serological immunity of individuals vaccinated against the Wuhan variant. The study also showed poorer immunity to Omicron than to Wuhan, but after the third vaccine dose, an increased cross-reactivity between the different covid variants was shown.
To strengthen the serological profiling of the donor plasma samples, Attana QCM was used to study the interaction kinetics between the ACE2 receptor and Wuhan and other variants (Alpha, Beta, Gamma, Delta, Epsilon and Kappa and Omicron). The affinity varied by more than an order of magnitude and clear differences in the interaction kinetics were observed. Overall, neutralization in Wuhan was among the strongest among the variants tested, which was expected as the vaccine was developed against the Wuhan variant. Significantly inferior neutralizing efficacy was observed against the Beta and Gamma strains compared to Wuhan at all time points tested up to 6 months post-vaccination. The average neutralization against all variants was just over 40%. The results also showed the following significant differences:
• Women showed better protection against all variants than men.
• 60 years and older showed a significantly lower protection compared to those under 40 years.
• Vaccinees of Indian ethnicity showed a small, but significantly stronger, peak response to the Gamma variant compared to those of Chinese ethnicity. In addition, differences were detected against the alpha and beta variants between these two cohorts. Although this needs to be validated in larger cohorts, this raises the possibility that significant ethnic differences in vaccine response may exist.
• Former, but not active, smokers showed higher protection compared to non-smokers.
• BMI and comorbidities such as high blood pressure and high cholesterol had no effect on the observed neutralizing titers.
For more information, please contact:
Marcus Söderberg
CEO Attana AB
ir@attana.com
+46 708 86 23 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags:
